Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2001

View Archived Issues

Abgenix discusses first-quarter highlights

Taiwan researchers study plant-derived sesquiterpene as potential antihypertensive agent

Electrophysiological profile of amiodarone homologues examined in guinea pig hearts

Gilead submits MAA for tenofovir DF in Europe

ICN considers licensing levovirin

Pharmacyclics reacquires worldwide rights to Lutrin

Sheffield initiates development of inhaled interferon gamma for respiratory diseases

Phase II trial of irofulven for treatment of glioma commences

Preclinical antiproliferative activity of A-105972 characterized

Antithrombotic activity of agkistin related to platelet gpIb antagonism

Cell Pathways and BMS to initiate drug combination study for first-line NSCLC

Atrix's periodontal disease treatment approved in several European countries

Cathepsin S inhibitor collaboration extended by Medivir, Genzyme; licensing partner sought

Novel approach to therapeutic HBV vaccine taken by StressGen

Sustained benefits seen for Visudyne therapy over three years of follow-up

First quarter at GenVec marked by progress in TNFerade and PEDF programs

Potential new hypnotic Ro-41-3696 tested in multiple-dose clinical study in elderly volunteers

Neurocrine Biosciences reports clinical development progress

Preclinical profile of Bay-59-8862, a new taxane, reviewed in Drugs of the Future

MAbs prepared at Genentech act as HGF receptor antagonists

French lab patents new nicotinic acetylcholine receptor subunit and uses thereof

Novel P2T receptor antagonists identified at AstraZeneca as potential antithrombotics

Theratechnologies and Alza to develop ThGRF in a Macroflux system

Inhibitors of factor Xa under development at Cor Therapeutics

Bayer describes dicarboxylic acid derivatives useful for cardiovascular disorders

Dermatological stilbene compounds in the Galderma pipeline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Harbour Biomed closes busy year with $1B+ BMS deal
BioWorld
Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...